Status:
COMPLETED
A Relative Bioavailability Study of Citalopram 40 mg Tablets Under Fed Conditions
Lead Sponsor:
Actavis Inc.
Conditions:
Healthy
Eligibility:
MALE
18-50 years
Phase:
PHASE1
Brief Summary
The purpose of this study is to evaluate and compare the relative bioavailability, and therefore the bioequivalence of two formulations of Citalopram after a single dose administration under fed condi...
Detailed Description
Study Type: Interventional Study Design: Randomized, 2-period, 2-sequence, crossover design. Official Title: Single Dose Crossover Comparative Bioavailability Study of Citalopram 40 mg Tablets in Hea...
Eligibility Criteria
Inclusion
- Availability of subject for the entire study period and willingness to adhere to protocol requirements as evidenced by the informed consent form duly signed by the subject.
- Males aged from 18 to 50 years with a body mass index (BMI) within 19-30; demographic data (sex, age, ethnic group, body weight, height and smoking habits) will be recorded and reported in the final report.
- Clinical laboratory values within the laboratory's stated normal range; if not within this range, they must be without any clinical significance and must be recorded as such in the CRF.
- Healthy according to the laboratory results and physical examination
- Normal cardiovascular function according to ECG.
- Subjects should be non- or ex-smokers.
Exclusion
- Significant history of hypersensitivity to citalopram or any related products as well as severe hypersensitivity reactions (like angioedema) to any drugs.
- Presence or history of significant gastrointestinal, liver or kidney disease, or any other conditions known to interfere with the absorption, distribution, metabolism or excretion of drugs or known to potentiate or predispose to undesired effects.
- Presence or history of significant cardiovascular, pulmonary, hematologic, neurologic, psychiatric, endocrine, immunologic or dermatologic disease.
- Use of MAO inhibitors within 14 days of day 1 of the study
- Maintenance therapy with any drug, or significant history of drug dependency, alcohol abuse (\> 3 units of alcohol per day, intake of excessive alcohol, acute or chronic), or serious Psychological disease.
- Any clinically significant illness in the previous 28 days before day 1 of this study.
- Use of enzyme-modifying drugs in the previous 28 days before day 1 of this study (all barbiturates, corticosteroids, phenylhydantoins, etc.).
- Participation in another clinical trial in the previous 28 days before day 1 of this study.
- Donation of 500 mL or more of blood (Canadian Blood Services, Hema-Quebec, clinical studies, etc.) in the previous 56 days before day 1 of this study.
- Positive urine screening of drugs of abuse.
- Positive results to HIV, HBsAg or anti-HCV tests
- History of fainting upon blood sampling
Key Trial Info
Start Date :
June 1 2003
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
July 1 2003
Estimated Enrollment :
32 Patients enrolled
Trial Details
Trial ID
NCT00864890
Start Date
June 1 2003
End Date
July 1 2003
Last Update
August 17 2010
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Algorithme Pharma Inc.
Montreal, Quebec, Canada, H4N2Y8